Skip to main content

Table 3 Hormonal and metabolic parameters at the different stages of the study for the 4 types of LARCs evaluated

From: Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study

Parameter

LNG

ENG

CuID

SIUD

P value1

P value2

SHBG (nmol/L)

   

0.403

 < 0.001

 Stage 1

97.5 ± 79*

(68.8)

112.5 ± 73.7†

(84.4)

71.4 ± 51.2

(54.9)

100.4 ± 79.2£

(77)

  

 Stage 2

51.7 ± 17.1*

(52.6)

61.8 ± 18†

(63.5)

46.1 ± 13.4

(47.3)

38.2 ± 16.1£

(32.7)

  

Total testosterone (mg/dL)

  

0.301

0.141

 Stage 1

31.3 ± 21.2

(24.4)

26 ± 15.8

(21.2)

27.4 ± 17.1

(22.1)

25.3 ± 9.6

(24)

  

 Stage 2

33.5 ± 8.7

(32)

26.3 ± 7

(27.3)

32.3 ± 8.8

(31.6)

32.7 ± 8.8

(34.8)

  

Free testosterone (mg/dL)

   

0.519

0.941

 Stage 1

0.4 ± 0.5

(0.2)

0.3 ± 0.3

(0.2)

1 ± 2.5

(0.3)

1.1 ± 3.9

(0.2)

  

 Stage 2

0.3 ± 0.3

(0.3)

0.3 ± 0.1

(0.3)

1.8 ± 5.8

(0.3)

0.4 ± 0.2

(0.3)

  

TSH (mU/L)

   

0.833

0.327

 Stage 1

2.1 ± 1

(1.8)

2 ± 1

(1.6)

2.1 ± 1.7

(1.5)

2.5 ± 1.9

(2.1)

  

 Stage 2

2.1 ± 0.7

(2.2)

2.2 ± 0.8

(2.1)

1.9 ± 1

(1.6)

1.7 ± 0.7

(1.7)

  

Free T4 (ng/dL)

   

0.577

0.249

 Stage 1

0.9 ± 0.2

(0.9)

0.9 ± 0.3

(0.9)

1 ± 0.3

(1)

1 ± 0.2

(1)

  

 Stage 2

0.9 ± 0.2

(0.9)

1.1 ± 0.2

(1.1)

1.1 ± 0.2

(1.1)

1 ± 0.2

(1)

  

Prolactin (ng/mL)

   

0.458

0.100

 Stage 1

19.3 ± 18.8

(12.1)

20.5 ± 15.1

(13.9)

17.9 ± 13.6

(12.6)

14.9 ± 9.6

(10.9)

  

 Stage 2

10.8 ± 5.1

(9.3)

12.5 ± 5.6

(11.2)

11.6 ± 5.8

(9.3)

10.1 ± 3.2

(9.4)

  

Insulin (mU/L)

   

0.234

0.534

 Stage 1

7.4 ± 3.1

(6.6)

6.5 ± 4.9

(5.4)

6.7 ± 3.8

(6)

6.6 ± 5.1

(5.3)

  

 Stage 2

6.3 ± 1.7

(6.4)

6.6 ± 2.2

(5.7)

6.9 ± 3.1

(6.2)

6.2 ± 3

(5.3)

  

HDL (mg/dL)

   

0.058

0.922

 Stage 1

59 ± 16.6

(54)

55 ± 12.4

(55)

58.1 ± 15.9

(55)

62.1 ± 16.2

(59)

  

 Stage 2

60.8 ± 11.7

(57)

53.1 ± 10.8

(52)

60.5 ± 11

(55)

60.8 ± 11.3

(55)

  

Triglycerides (mg/dL)

   

0.398

0.471

 Stage 1

84.5 ± 40.7

(71.5)

98.5 ± 47.8

(100)

72.5 ± 36.6

(66.5)

85.9 ± 38.2

(70)

  

 Stage 2

83.5 ± 23.5

(78)

86.1 ± 27.5

(85)

75.8 ± 24.8

(73.5)

78.8 ± 26.6

(71)

  

LDL(mg/dL)

   

0.314

0.495

 Stage 1

97.7 ± 22.5

(100.5)

93.6 ± 30.4

(88)

105.3 ± 26.7

(100.5)

101.1 ± 21.7

(100)

  

 Stage 2

103.6 ± 21.5

(103)

93.1 ± 22.5

(88)

107.5 ± 24

(101)

103.1 ± 16.2

(105)

  

Fasting glycemia (mg/dL)

  

0.827

0.456

 Stage 1

82 ± 6.7

(82.5)

80.6 ± 6.3

(83)

79.3 ± 9

(79.5)

80.8 ± 7.5

(81.5)

  

 Stage 2

80.4 ± 4.1

(81)

78.9 ± 9.6

(82)

80.1 ± 5.2

(81)

80.1 ± 4.4

(81)

  

Glycatedhemoglobin (%)

   

0.359

0.477

 Stage 1

5.3 ± 0.4

(5.3)

5.1 ± 0.3

(5.1)

5.4 ± 0.4

(5.5)

5.3 ± 0.3

(5.2)

  

 Stage 2

5.2 ± 0.4

(5.2)

5.2 ± 0.2

(5.3)

5.2 ± 0.3

(5.2)

5.3 ± 0.3

(5.2)

  

Hemoglobin (g/dL)

   

0.638

0.224

 Stage 1

13.4 ± 0.8 (13.6)

13.4 ± 1.3

(13.2)

13.7 ± 0.8

(13.7)

13.4 ± 0.8

(13.5)

  

 Stage 2

13.8 ± 0.6

(14.1)

13.7 ± 0.8

(13.5)

13.2 ± 0.6

(13.2)

15 ± 7

(13.2)

  
  1. LNG levonorgestrel intrauterine system, ENG etonogestrel-releasing implant, CuIUD copper intrauterine device, SIUD silver intrauterine device. P value 1refers to comparison between the LARC types and p value 2refers to comparison between stages. Symbols *,†, £indicates pairs with significative differences in post-hoc test. Data presented as mean ± SD (median)